Examples of using Keytruda in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
How does Keytruda work?
If you miss an appointment to get KEYTRUDA.
How is Keytruda used?
Keytruda is a cancer medicine used to treat adults with.
It is not known if KEYTRUDA passes into your breast milk.
Feeling tired orweak is a very common side effect of KEYTRUDA.
Why is Keytruda approved?
A second studylooked at 834 patients with melanoma who received either Keytruda or another medicine, ipilimumab.
KEYTRUDA must not be administered as an intravenous push or bolus injection.
Do not stop treatment with KEYTRUDA unless you have discussed this with your doctor.
KEYTRUDA should not to be used in children and adolescents below 18 years of age.
With respect to NSCLC, the CHMP noted that Keytruda helps prolong survival and slows the worsening of the disease.
KEYTRUDA contains the active substance pembrolizumab, which is a monoclonal antibody.
The first clinical study,an open label Phase I study of MRx0518 in combination with Keytruda® and conducted in collaboration with Merck& Co., Inc., Kenilworth, NJ.
Keytruda is specifically for lung tumours that produce a protein known as PD-L1.
Early results from this study showed that the patients treated with Keytruda lived for up to 5.5 months without their disease getting worse compared with 2.8 months with ipilimumab.
Keytruda has been shown to be effective in treating patients with melanoma and non-small cell lung cancer.
In a highly anticipated study, Incyte reported that Epacadostat, tested in combination with Keytruda in patients with unresectable or metastatic melanoma, did not add benefit over Keytruda monotherapy.
Reconstituted KEYTRUDA is a clear to slightly opalescent, colourless to slightly yellow solution.
The open label Phase I study will evaluate the safety,tolerability and preliminary clinical benefit of the combination of MRx0518 and Keytruda® in up to 132 participants who have progressed on prior PD-1 inhibitor therapy and will take place at the MD Anderson Cancer Center in Texas, US.
Treatment with Keytruda must be started and supervised by a doctor experienced in the treatment of cancer.
In patients whose tumours tested strongly for PD-L1,overall survival was higher after Keytruda treatment(around 15 months) than after treatment with another cancer medicine docetaxel around 8 months.
Keytruda was also effective in the larger group of patients with lung cancer, including those whose tumours were not strongly positive for PD-L1.
The clinical trial testing NOX-A12 as monotherapy and in combination with Keytruda is being conducted at one of the leading centers for cancer research and treatment, the National Center for Tumor Diseases in Heidelberg, Germany.
KEYTRUDA is a humanised monoclonal antibody which binds to the programmed cell death-1(PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2.
Since September 2014, the Keytruda preparation has been approved in the USA for the treatment of skin cancer melanoma.
KEYTRUDA is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma(NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen.
Other common side effects of Keytruda related to the activity of the immune system causing inflammation of body organs.
The safety profile of Keytruda in lung cancer patients is similar to that in melanoma patients and its overall safety compares well with that of docetaxel.
All prescribers of KEYTRUDA must be familiar with the Physician Information and Management Guidelines.